MedTrace Logo

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation

NCT03518047 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-01-25

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.

Conditions

Interventions

DRUG

risankizumab

rizankizumab subcutaneous (SC) infusion

DRUG

placebo for rizankizumab

placebo for rizankizumab subcutaneous (SC) infusion

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-19
Primary Completion
2020-02-11
Completion
2020-02-11

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03518047 on ClinicalTrials.gov